Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T84160
(Former ID: TTDS00106)
|
|||||
Target Name |
5-HT 3 receptor (5HT3R)
|
|||||
Synonyms |
5-hydroxytryptamine receptor type 3; 5-hydroxytryptamine receptor 3; 5-HT3R; 5-HT3 receptor; 5-HT-3
Click to Show/Hide
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Nausea/vomiting [ICD-11: MD90] | |||||
Function |
This is one of the several different receptors for 5- hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel.
Click to Show/Hide
|
|||||
BioChemical Class |
GPCR rhodopsin
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 4 Approved Drugs | + | ||||
1 | Granisetron | Drug Info | Approved | Nausea and vomiting | [2] | |
2 | Ondansetron | Drug Info | Approved | Chemotherapy-induced nausea | [3], [4] | |
3 | Ramosetron | Drug Info | Approved | Nausea and vomiting | [2], [5] | |
4 | Y-25130 | Drug Info | Approved | Nausea and vomiting | [2], [6], [7] | |
Clinical Trial Drug(s) | [+] 16 Clinical Trial Drugs | + | ||||
1 | Lerisetron | Drug Info | Phase 3 | Vomiting | [8] | |
2 | LITOXETINE | Drug Info | Phase 3 | Mood disorder | [9] | |
3 | Pancopride | Drug Info | Phase 3 | Nausea | [10] | |
4 | Renzapride | Drug Info | Phase 3 | Irritable bowel syndrome | [11], [12] | |
5 | Zatosetron maleate | Drug Info | Phase 3 | Anxiety disorder | [13] | |
6 | AD04 | Drug Info | Phase 2 | Alcohol dependence | [14] | |
7 | DDP-225 | Drug Info | Phase 2 | Irritable bowel syndrome | [12] | |
8 | KB-6806 | Drug Info | Phase 2 | Chemotherapy-induced nausea | [8] | |
9 | Lintopride | Drug Info | Phase 2 | Nausea | [15] | |
10 | Pumosetrag | Drug Info | Phase 2 | Irritable bowel syndrome | [12] | |
11 | ADR-851 | Drug Info | Phase 1 | Nausea and vomiting | [16] | |
12 | BIMU-1 | Drug Info | Phase 1 | Cognitive impairment | [17], [18] | |
13 | CVN058 | Drug Info | Phase 1 | Schizophrenia | [19] | |
14 | ITASETRON | Drug Info | Phase 1 | Nausea | [20] | |
15 | TAK-058 | Drug Info | Phase 1 | Schizophrenia | [21] | |
16 | Tedatioxetine | Drug Info | Phase 1 | Major depressive disorder | [22] | |
Discontinued Drug(s) | [+] 17 Discontinued Drugs | + | ||||
1 | RG-12915 | Drug Info | Discontinued in Phase 3 | Nausea | [23] | |
2 | BRL-46470 | Drug Info | Discontinued in Phase 2 | Anxiety disorder | [24], [25] | |
3 | DAT-582 | Drug Info | Discontinued in Phase 2 | Nausea | [26] | |
4 | E-3620 | Drug Info | Discontinued in Phase 2 | Gastric motility disorder | [27] | |
5 | Fabesetron | Drug Info | Discontinued in Phase 2 | Irritable bowel syndrome | [28] | |
6 | Lurosetron | Drug Info | Discontinued in Phase 2 | Vomiting | [29] | |
7 | SR-57227 | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [30], [31] | |
8 | Mirisetron maleate | Drug Info | Discontinued in Phase 1 | Anxiety disorder | [32] | |
9 | SEP-226332 | Drug Info | Discontinued in Phase 1 | Obstructive sleep apnea | [33] | |
10 | WAY-100289 | Drug Info | Discontinued in Phase 1 | Anxiety disorder | [34] | |
11 | BP4.879a | Drug Info | Terminated | Schizophrenia | [35] | |
12 | CR-3124 | Drug Info | Terminated | Substance use disorder | [36] | |
13 | GK-128 | Drug Info | Terminated | Vomiting | [37] | |
14 | GR-65630 | Drug Info | Terminated | Vomiting | [38] | |
15 | SC-52150 | Drug Info | Terminated | Vomiting | [39] | |
16 | SDZ-ICM-567 | Drug Info | Terminated | Anxiety disorder | [40] | |
17 | SRSS-021 | Drug Info | Terminated | Vomiting | [41] | |
Mode of Action | [+] 4 Modes of Action | + | ||||
Antagonist | [+] 15 Antagonist drugs | + | ||||
1 | Granisetron | Drug Info | [1], [42] | |||
2 | Y-25130 | Drug Info | [45] | |||
3 | Lerisetron | Drug Info | [8] | |||
4 | AD04 | Drug Info | [14] | |||
5 | KB-6806 | Drug Info | [8] | |||
6 | CVN058 | Drug Info | [53] | |||
7 | TAK-058 | Drug Info | [2], [54] | |||
8 | RG-12915 | Drug Info | [55] | |||
9 | DAT-582 | Drug Info | [57] | |||
10 | SEP-226332 | Drug Info | [62] | |||
11 | BP4.879a | Drug Info | [64] | |||
12 | SDZ-ICM-567 | Drug Info | [69] | |||
13 | SRSS-021 | Drug Info | [70] | |||
14 | BRL 43694A | Drug Info | [72] | |||
15 | Ciproxifan | Drug Info | [73] | |||
Agonist | [+] 1 Agonist drugs | + | ||||
1 | Ondansetron | Drug Info | [43] | |||
Modulator | [+] 26 Modulator drugs | + | ||||
1 | Ramosetron | Drug Info | [44] | |||
2 | LITOXETINE | Drug Info | [46] | |||
3 | Renzapride | Drug Info | [48] | |||
4 | Zatosetron maleate | Drug Info | [49] | |||
5 | DDP-225 | Drug Info | [50] | |||
6 | Lintopride | Drug Info | [15] | |||
7 | Pumosetrag | Drug Info | [51] | |||
8 | ADR-851 | Drug Info | [52] | |||
9 | BIMU-1 | Drug Info | [18] | |||
10 | ITASETRON | Drug Info | [50] | |||
11 | Tedatioxetine | Drug Info | [50] | |||
12 | BRL-46470 | Drug Info | [56] | |||
13 | E-3620 | Drug Info | [50] | |||
14 | Fabesetron | Drug Info | [58] | |||
15 | Lurosetron | Drug Info | [59] | |||
16 | SR-57227 | Drug Info | [60] | |||
17 | Mirisetron maleate | Drug Info | [61] | |||
18 | WAY-100289 | Drug Info | [63] | |||
19 | CR-3124 | Drug Info | [65] | |||
20 | GK-128 | Drug Info | [66] | |||
21 | GR-65630 | Drug Info | [67] | |||
22 | SC-52150 | Drug Info | [68] | |||
23 | (R)-zacopride | Drug Info | [71] | |||
24 | S-21007 | Drug Info | [74] | |||
25 | SC-52491 | Drug Info | [75] | |||
26 | SC-54750 | Drug Info | [75] | |||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | Pancopride | Drug Info | [47] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7. | |||||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2290). | |||||
REF 4 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2301). | |||||
REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2285). | |||||
REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000557) | |||||
REF 8 | Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. | |||||
REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001264) | |||||
REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001751) | |||||
REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 244). | |||||
REF 12 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | |||||
REF 13 | Concise Dictionary of Pharmacological Agents: Properties and Synonyms, Dr. Ian Morton,I.K. Morton,Judith M. Hall. Page(298). | |||||
REF 14 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 15 | The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9. | |||||
REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001323) | |||||
REF 17 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 234). | |||||
REF 18 | Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. | |||||
REF 19 | ClinicalTrials.gov (NCT03669250) CVN058 Effect on Mismatch Negativity in Schizophrenics. U.S. National Institutes of Health. | |||||
REF 20 | ClinicalTrials.gov (NCT02259985) Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects. U.S. National Institutes of Health. | |||||
REF 21 | ClinicalTrials.gov (NCT02389881) Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants. U.S. National Institutes of Health. | |||||
REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023694) | |||||
REF 23 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001786) | |||||
REF 24 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2302). | |||||
REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001328) | |||||
REF 26 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001226) | |||||
REF 27 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004004) | |||||
REF 28 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001434) | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002948) | |||||
REF 30 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4316). | |||||
REF 31 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001602) | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003649) | |||||
REF 33 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020129) | |||||
REF 34 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001552) | |||||
REF 35 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||||
REF 36 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024202) | |||||
REF 37 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002051) | |||||
REF 38 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003534) | |||||
REF 39 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001830) | |||||
REF 40 | Determination of SDZ ICM 567 in blood and muscle microdialysis samples by microbore liquid chromatography with ultraviolet and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1997 Oct 24;700(1-2):191-200. | |||||
REF 41 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019090) | |||||
REF 42 | Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1993 Apr;7(2):175-80. | |||||
REF 43 | Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70. | |||||
REF 44 | Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12. | |||||
REF 45 | The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305. | |||||
REF 46 | Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45. | |||||
REF 47 | Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64. | |||||
REF 48 | Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. | |||||
REF 49 | Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31. | |||||
REF 50 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 51 | Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.Neurogastroenterol Motil.2014 Jan;26(1):13-20. | |||||
REF 52 | Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol. 1991 Oct 29;204(1):117-9. | |||||
REF 53 | Clinical pipeline report, company report or official report of Cerevance. | |||||
REF 54 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040805) | |||||
REF 55 | Cataractogenesis in rats induced by in utero exposure to RG 12915, a 5-HT3 antagonist. Fundam Appl Toxicol. 1995 Sep;27(2):270-6. | |||||
REF 56 | Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron. Br J Pharmacol. 1995 Sep;116(2):1781-8. | |||||
REF 57 | 5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. Eur J Pharmacol. 1992 Jun 17;216(3):435-40. | |||||
REF 58 | Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993 May;265(2):752-8. | |||||
REF 59 | US patent application no. 7,932,267, Use of α-glucosidase inhibitors to treat alphavirus infections. | |||||
REF 60 | Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents. J Neural Transm Gen Sect. 1995;102(2):83-90. | |||||
REF 61 | The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging. 1997 Jan-Feb;18(1):21-8. | |||||
REF 62 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020129) | |||||
REF 63 | The selective 5-HT3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl). 1995 Feb;117(3):318-32. | |||||
REF 64 | 5-HT(3A) receptor subunit is required for 5-HT3 antagonist-induced reductions in alcohol drinking. Neuropsychopharmacology. 2004 Oct;29(10):1807-13. | |||||
REF 65 | Physicochemical and biopharmaceutical characterization of endo-2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-1H-benz[e]isoindol-1-one (CR312... J Pharm Sci. 2006 Dec;95(12):2706-21. | |||||
REF 66 | Effect of a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, GK-128, on 5-HT3 receptors mediating contractions and relaxations in guinea-pig distal colon. Gen Pharmacol. 1997 Sep;29(3):353-9. | |||||
REF 67 | Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol. 1989 Jan 10;159(2):157-64. | |||||
REF 68 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001830) | |||||
REF 69 | Microdialysis sampling to determine the pharmacokinetics of unbound SDZ ICM 567 in blood and brain in awake, freely-moving rats. Pharm Res. 1995 Feb;12(2):291-4. | |||||
REF 70 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019090) | |||||
REF 71 | R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):283-9. | |||||
REF 72 | BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy. Schweiz Med Wochenschr. 1989 Jun 10;119(23):831-4. | |||||
REF 73 | The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. | |||||
REF 74 | Effects of S-21007, a potent 5-HT3 partial agonist, in mouse anxiety. Zhongguo Yao Li Xue Bao. 1999 Sep;20(9):805-12. | |||||
REF 75 | Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.